论文部分内容阅读
目的 :探讨慢性乙肝的治疗和保肝药物效果 ,拓宽用药途径。方法 :凯西莱组 90例 ,静滴凯西莱 2 0 0mg ,1次 /天 ,30天为一疗程 ;齐墩果酸片组 6 0例 ,口服齐墩果酸片 ,4 0mg ,3/天 ,静滴能量合剂 2支+10 %葡萄糖 5 0 0ml,30天为一疗程 ,两组进行效果对比。结果 :经 1个月治疗 ,凯西莱组在症状、体征及丙氨酸转氨酶、胆红素、清蛋白 /球蛋白、γ球蛋白均较齐墩果酸片组要好 ,两者比较 ,差异显著 (P <0 0 5 ) ;两组腹水吸收情况相比 ,无显著差异 (P >0 0 5 )。结论 :凯西莱治疗慢性乙肝 ,疗效确切 ,安全性好
Objective: To explore the therapeutic effect of chronic hepatitis B and hepatoprotective drugs, broaden the use of drugs. Methods: 90 cases of Kesilai group were treated with intravenous ketaxale 200 mg once a day for 30 days. 60 cases of oleanolic acid tablets group were orally administered with oleanolic acid tablets, 40 mg, 3 mg / Day, intravenous infusion of energy mixture 2 +10% glucose 500ml, 30 days for a course of treatment, the two groups were compared. Results: After 1 month of treatment, the symptoms and signs and the contents of alanine aminotransferase, bilirubin, albumin / globulin and γ-globulin in the Cassis group were better than those in the oleanolic group, (P <0.05). There was no significant difference between the two groups in the absorption of ascites (P> 0.05). Conclusion: Kesilai treatment of chronic hepatitis B, the exact effect, good safety